Our ML/AI enabled platform transforms life-changing therapies into accessible oral formulations.
Our oral biologic platform creates substantial value across the entire healthcare ecosystemโfrom patients to payers to providers.
Eliminates needle anxiety, provides greater convenience and autonomy, reduces pain and infection risk, improves treatment adherence, and offers more physiological drug delivery for better therapeutic outcomes.
Reduces unit costs through simplified manufacturing, eliminates administration fees for infusion centers and nursing time, decreases complication costs, and drives competitive markets that lower prices across therapeutic classes.
Reduces burden on clinical staff, optimizes facility use by freeing infusion chairs and clinic space, eliminates medical waste from disposables, and enables earlier disease intervention to prevent costly hospitalizations.
Leveraging machine learning and artificial intelligence to revolutionize how biologics are formulated and delivered in the small intestine for maximum local and systemic bioavailability.
Traditional formulation development relies on trial-and-error approaches that take years and millions of dollars. Our ML platform analyzes thousands of molecular interactions simultaneously, predicting optimal formulation parameters in weeks, not years.
By integrating physicochemical properties, biological pathways, and delivery kinetics, our AI identifies the precise combination of excipients, protective coatings, and release mechanisms needed for each unique biologic.
AI algorithms predict formulation success rates before synthesis
Machine learning accelerates formulation cycles from years to months
Continuous learning from experimental results improves platform accuracy
ML models generate optimal excipient combinations and coating strategies for intestinal delivery
Virtual simulations predict gastric protection and intestinal release for maximum bioavailability
Experimental data feeds back into models for continuous improvement and optimization
Our diverse pipeline targets multiple high-impact therapeutic areas with significant unmet medical needs.
Oral anti-TNF monoclonal antibody formulation
Oral integrin antagonist for Crohn's and UC
Oral PCSK9 inhibitor for cardiovascular disease prevention
Oral checkpoint inhibitor immunotherapy platform
We're actively seeking strategic partnerships with pharmaceutical companies, research institutions, and investors who share our vision of transforming biologic drug delivery.
Interested in partnering with Oralyx Bio? We'd love to explore collaboration opportunities in drug development, licensing, or investment.
Contact UsWorld-class expertise in drug formulation, ML/AI, and drug-device combination products.
Former VP of Formulation Sciences at a leading biotech company with 15+ years developing novel drug delivery systems. Led development of 12 approved products and holds multiple patents in oral biologic delivery. PhD in Pharmaceutical Sciences from MIT.
Leading venture firms invest in revolutionary oral biologic delivery platform, accelerating pipeline development and bringing the company's ML-enabled formulation technology closer to clinical trials.
Interested in partnerships, investment opportunities, or learning more? We'd love to hear from you.
Malvern, PA 19355
United States
info@oralyxbio.com
partnerships@oralyxbio.com